Eculizumab as a Treatment for Hyper-Haemolytic and Aplastic Crisis in Sickle Cell Disease
Ishan Patel1,Mihir Odak2, Steven Douedi2, Abbas Alshami2, Vandan D Upadhyaya2, Mohammad Hossain2, Madhurima Anne3 Swapnil V Patel2
1 Department of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
2 Department of Medicine, Hackensack Meridian Jersey Shore University Medical Center, Neptune, NJ, USA
3 Department of Hematology Oncology, Hackensack Meridian Jersey Shore University Medical Center, Neptune, NJ, USA
Doi: 10.12890/2021_002824 - European Journal of Case Reports in Internal Medicine - © EFIM 2021
Received: 08/08/2021
Accepted: 26/08/2021
Published: 07/10/2021

How to cite this article: Patel I, Odak M, Douedi S, Alshami A, Upadhayaya VD, Hossain M, Anne M, Patel SV. Eculizumab as a treatment for hyper haemolytic and aplastic crisis in sickle cell disease. EJCRIM 2021;8 doi:10.12890/2021_002824.

Conflicts of Interests: The authors declare there are no competing interests.
This article is licensed under a Commons Attribution Non-Commercial 4.0 License


Background: Patients with sickle cell disease can experience various crises including sequestration crisis, haemolytic crisis and aplastic crisis. Due to alloantibody formation, transfusion alloantibodies can cause a haemolytic crisis. Treatment involves avoiding packed red blood cell transfusions, as well as intravenous immunoglobulin, steroids and eculizumab to decrease the chances of haemolysis.
Case description: We report the case of a 42-year-old man who was found to have worsening anaemia after packed red blood cell transfusion with evidence suggestive of haemolytic crisis. Due to reticulocytopenia, aplastic crisis was also suspected and later confirmed via parvovirus IgG and IgM titres. The patient did not improve with steroid and intravenous immunoglobulin therapy and was treated with eculizumab as a salvage therapy.
Conclusion: Concurrent hyper-haemolytic crisis and aplastic crisis should be suspected in patients with features of haemolysis and reticulocytopenia. Prompt recognition and treatment with eculizumab are paramount in those who fail steroid and intravenous immunoglobulin treatment.



Sickle cell disease, hyper-hemolysis, eculizumab, aplastic anemia


Sickle cell disease is a chronic multisystem disease characterized by vaso-occlusive phenomena and haemolysis [1]. These clinical manifestations are due to a point mutation in the beta globin gene that causes haemoglobin polymerization [1, 2]. The most common cause for hospital admissions is painful vaso-occlusive phenomena [3]. Other clinical complications include acute chest syndrome, pulmonary hypertension, avascular necrosis, heart disease and renal failure [4, 5].
Sickle cell disease is known to produce a chronic haemolytic anaemia that can acutely worsen with blood transfusion [5, 6]. The major precipitating factors for acute anaemia are aplastic crisis, splenic sequestration crisis and hyper-haemolytic crisis [6, 7]. Alloimmunization may occur as a result of transfusions in patients being treated for acute haemolytic crisis [6]. Delayed hypersensitivity transfusion reactions and hyper-haemolytic syndrome must be readily recognized as further packed red blood cell transfusions can increase mortality in these patients [6, 7]. We present the case of a 42-year-old man with sickle cell disease who developed acute anaemia and reticulocytopenia following packed red blood cell transfusion which improved following eculizumab therapy.


A 42-year-old man with a medical history of sickle cell disease, complicated by avascular necrosis of bilateral hips, and rheumatoid arthritis presented to the hospital with complaints of fevers, fatigue and dyspnoea for 1 week. He reported no chest pain, joint pain, cough or sick contacts. On admission he was febrile to 38.3°C, had a heart rate of 102 beats per minute, and pulse oximetry of 95% on room air. Physical examination noted conjunctival pallor and mild rales in bilateral lung fields. Chest x-ray showed mild bilateral interstitial infiltrates. Laboratory analysis revealed a haemoglobin of 5.3 g/dl (normal range 13.2–17.5 g/dl) with an absolute reticulocyte count of 0.043 µl (normal range 0.010–0.110 µl) and a white blood cell count of 8.0 (normal range 4.5–11 k/µl). The patient was started on vancomycin and piperacillin-tazobactam after blood cultures were obtained and an intravenous fluid bolus was given for possible sepsis. Parvovirus IgG and IgM titres were also obtained due to concern of aplastic crisis. He was transfused with two units of packed red blood cells and was started on erythropoietin due to reticulocytopenia. Post-transfusion haemoglobin was 5.0 g/dl. Typing and cross-matching revealed antibodies to blood products.
Due to an inadequate response to transfusions, haemolytic work-up was pursued (Table 1).

Figure 1 (click to enlarge)

Table 1. Haemolytic work-up values

The patient was started on methylprednisolone and intravenous immunoglobulin for 5 days. He subsequently developed worsening fatigue, jaundice and hypoxia. Haemoglobin remained low despite corticosteroid and intravenous immunoglobulin therapy. Eculizumab 900 mg was then started. Subsequent parvovirus IgG and IgM titres were elevated, suggesting concurrent aplastic crisis.
After initiation of eculizumab, the patient’s clinical status improved. He was subsequently discharged on a prednisone taper and haematology referral.


Acute transfusion reactions usually occur during or immediately after transfusion [8]. Symptoms may include chills, fever, hypotension, haemoglobinuria and renal failure. Complications like delayed hypersensitivity transfusion reactions with hyper-haemolysis occur 5–20 days after transfusion [9].
Hyper-haemolysis is a rare but often a fatal complication of sickle cell disease. It is characterized by severe anaemia with a post-transfusion decrease in haemoglobin [10]. Findings include destruction of donor and recipient packed red blood cells, low reticulocyte counts, and negative Coombs antibody assays [8]. Our patient developed aplastic anaemia from acute parvovirus infection, with hyper-haemolytic crisis from a delayed transfusion reaction.
Multiple mechanisms have been postulated as the cause of hyper-haemolysis including bystander red blood cell haemolysis via antibody formation against human leukocyte antigen protein and complement pathway, and macrophage-mediated destruction of red blood cells [8]. Bystander haemolysis is thought to be due to formation of antigens of non-red blood cells leading to complex formation with red blood cells, making sickle cells more vulnerable to complement-mediated destruction [8]. Macrophage-mediated hyper-haemolysis is thought to be due to macrophage interaction with vascular cell adhesion molecule-1 molecules on sickle reticulocytes [8].
The management of hyper-haemolysis includes conservative transfusion strategies as additional transfusions may lead to worsening haemolysis [8]. Our patient was managed conservatively after transfusion with three units of packed red blood cell due to concern for additional haemolysis as well as due to lack of compatible packed red blood cell availability. Intravenous immunoglobulin therapy has been proposed to reduce haemolysis by accelerated clearance of endogenous pathogenic auto-antibodies and inhibition of components of the complement cascade [12]. Corticosteroids are also used to reduce autoimmune-mediated haemolysis [8]. Rituximab has also been used for the treatment of delayed transfusion reactions [12, 13].
Eculizumab has been used successfully to treat delayed hypersensitivity transfusion reaction. As a C5-convertase inhibitor, it inhibits the complement cascade. Treatment with two doses of eculizumab was used in three patients reported by Dumas et al. [14]. Boonyasampant et al. reported the first case treated with eculizumab [15]. Severe delayed hypersensitivity transfusion reaction was defined as acute chest syndrome with worsening hypoxia or acute pulmonary hypertension, stroke or end organ damage [16]. Our patient’s improvement after eculizumab suggests involvement of the complement pathway in this reaction. Establishment of a gold standard therapy in such a cohort requires further study into delayed hypersensitivity transfusion reaction and eculizumab.


Hyper-haemolysis is a rare and often fatal type of delayed hypersensitivity transfusion reaction in patients with sickle cell disease. Eculizumab may show promise as the treatment for delayed hypersensitivity transfusion reaction in these patients. Further research should be done regarding the use of this monoclonal antibody as a possible medication of choice in this rare disease process.

  1. Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med 2017 Apr 20;376(16):1561–1573. doi: 10.1056/NEJMra1510865.
  2. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010 Dec 11;376(9757):2018–2031. doi: 10.1016/S0140-6736(10)61029-X.
  3. Yale SH, Nagib N, Guthrie T. Approach to the vaso-occlusive crisis in adults with sickle cell disease. Am Fam Physician 2000 Mar 1;61(5):1349–1356, 1363–1364. Erratum in: Am Fam Physician 2001 Jul 15;64(2):220.
  4. Chakravorty S, Williams TN. Sickle cell disease: a neglected chronic disease of increasing global health importance. Arch Dis Child 2015 Jan;100(1):48–53. doi: 10.1136/archdischild-2013-303773.
  5. Matthie N, Jenerette C. Sickle cell disease in adults: developing an appropriate care plan. Clin J Oncol Nurs 2015 Oct;19(5):562–567. doi: 10.1188/15.CJON.562-567.
  6. Panch SR, Montemayor-Garcia C, Klein HG. Hemolytic transfusion reactions. N Engl J Med 2019 Jul 11;381(2):150–162. doi: 10.1056/NEJMra1802338.
  7. Talano JA, Hillery CA, Gottschall JL, Baylerian DM, Scott JP. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics 2003 Jun;111(6 Pt 1):e661–665. doi: 10.1542/peds.111.6.e661.
  8. Aragona E, Kelly MJ. Hyperhemolysis in sickle cell disease. J Pediatr Hematol Oncol 2014 Jan;36(1):e54–56. doi: 10.1097/MPH.0b013e31828e529f.
  9. Vidler JB, Gardner K, Amenyah K, Mijovic A, Thein SL. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience. Br J Haematol 2015 Jun;169(5):746–753. doi: 10.1111/bjh.13339.
  10. Banks M, Shikle J. Hyperhemolysis syndrome in patients with sickle cell disease. Arch Pathol Lab Med 2018 Nov;142(11):1425–1427. doi: 10.5858/arpa.2017-0251-RS.
  11. Rhoades CJ, Williams MA, Kelsey SM, Newland AC. Monocyte-macrophage system as targets for immunomodulation by intravenous immunoglobulin. Blood Rev 2000 Mar;14(1):14–30. doi: 10.1054/blre.1999.0121.
  12. Bachmeyer C, Maury J, Parrot A, Bachir D, Stankovic K, Girot R, et al. Rituximab as an effective treatment of hyperhemolysis syndrome in sickle cell anemia. Am J Hematol 2010 Jan;85(1):91–92. doi: 10.1002/ajh.21578.
  13. Noizat-Pirenne F, Bachir D, Chadebech P, Michel M, Plonquet A, Lecron J-C, et al. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease. Haematologica 2007 Dec;92(12):e132–135. doi: 10.3324/haematol.12074.
  14. Dumas G, Habibi A, Onimus T, Merle J-C, Razazi K, Mekontso Dessap A, et al. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood 2016 Feb 25;127(8):1062–1064. doi: 10.1182/blood-2015-09-669770.
  15. Boonyasampant M, Weitz IC, Kay B, Boonchalermvichian C, Liebman HA, Shulman IA. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab. Transfusion 2015 Oct;55(10):2398–2403. doi: 10.1111/trf.13144.
  16. Pirenne F, Yazdanbakhsh K. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. Blood 2018 Jun 21;131(25):2773–2781. doi: 10.1182/blood-2018-02-785964.